Introduction to Severe Combined Immunodeficiencies (SCID) and Newborn Screening for SCID
Click CC to turn on closed captioning.
Once diagnosed accurately, newborns with SCID/T cell lymphopenia can appropriate management including life-sustaining treatment. Delays in identification of affected infants rapidly reduce the success of such treatments and significantly increase mortality. In Part 2 of this 2-part presentation, Dr. Abraham discusses the use of appropriate laboratory tests and test interpretation tools for follow-up of abnormal newborn screen for SCID/T cell lymphopenia cases.
- Roshini Abraham, PhD
- Associate Professor of Laboratory Medicine/Pathology and Medicine at Mayo Clinic
- Consultant in the Division of Clinical Biochemistry and Immunology at Mayo Clinic in Rochester, Minnesota
- Director of the Cellular and Molecular Immunology Laboratory within the Department of Laboratory Medicine and Pathology
- Director of the Jeffrey Modell Foundation for Primary Immunodeficiencies Diagnostic and Research Center at the Mayo Clinic
The SCID Series
- Hot Topic: Introduction to Severe Combined Immunodeficiencies (SCID) and Newborn Screening for SCID, Part 1
- Hot Topic: Introduction to Severe Combined Immunodeficiencies (SCID) and Newborn Screening for SCID, Part 2
- TREC/87959 T-Cell Receptor Excision Circles (TREC) Analysis for Immune Reconstitution
- CD4RT/89504 CD4 T-Cell Recent Thymic Emigrants (RTE)
- TBBS/9336 T- and B-Cell Quantitation by Flow Cytometry
- LPMGF/60591 Lymphocyte Proliferation to Mitogens, Blood
- TCP/89319 T-Cell Subsets, Naive, Memory and Activated
Forward to a Colleague
Share this presentation with:
- General Practitioners
If you have questions, email .